No matter whether patients had CAD or not, the simpler regimen was linked to less mortality and major bleeding at 6 months.

The data thus far suggest fewer repeat interventions with the newly FDA approved resorbable device compared with PTA.

WASHINGTON, DC—For vascular closure after transfemoral TAVI, a strategy that combines suture- and plug-based devices halves ...

WASHINGTON, DC—How patients weigh the opinions of their family and friends when making decisions about PAD varies by sex and ...

With further refinement and defined thresholds for treatment, this technology has the potential to guide treatment decisions.

Conference news filled our list this month, dominated by TCT 2024, although two EACTS stories also cracked our top 10.

Fewer rehospitalizations and better functional and QoL outcomes point to TAVI as a good choice, but longer-term data are ...

Ami Bhatt and Michael Mack explore the ethics of AI use in the detection of subclinical cardiovascular disease.

Ami Bhatt and Michael Mack explain the economics of AI use in the detection of subclinical cardiovascular disease.

The analysis wasn’t prespecified, and with no clear explanation, the field awaits insights from the larger BHF PROTECT-TAVI ...

A new analysis reveals where bleeds are most likely to happen and offers some surprising insights on their link with ...

The inability of QFR to rival FFR for 1-year MACE is a reminder of the need for large studies, even when new tech is enticing ...